Collectively, our findings indicate that UBE2D1-driven CD14<sup>+</sup>CXCL10<sup>+</sup> monocytes are central to sJIA pathogenesis and may represent both a biomarker and a therapeutic target for disease monitoring and intervention. Here, CD14 is linked to systemic-onset juvenile idiopathic arthritis.